In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...